LeMaitre Vascular Inc（LMAT）資訊與事件

$80.450

+0.796 (+0.99%)收盤時

LMAT 資訊

1.008-27Newsfilter

LeMaitre Vascular to Participate in Upcoming Investor Conferences

1.008-06Globenewswire

LeMaitre Vascular to Host Investor Meetings at Needham Conference

1.008-06Newsfilter

LeMaitre Vascular to Hold Investor Meetings at Needham Conference

9.508-05seekingalpha

LeMaitre Vascular Q2 2026 Earnings Call Insights

9.507-14Newsfilter

LeMaitre Vascular to Release Q2 2026 Financial Results on August 4

6.505-23Yahoo Finance

LeMaitre Stock Performance Analysis and Outlook

1.005-20Newsfilter

LeMaitre Vascular to Participate in Investor Conferences

9.505-06seekingalpha

LeMaitre Vascular Reports Strong Q1 2026 Earnings Growth and Strategic Outlook

9.505-05Yahoo Finance

LeMaitre Vascular Earnings Preview

1.004-07Newsfilter

LeMaitre Vascular to Present at Needham Healthcare Conference

查看更多資訊

LMAT 事件

8/5 12:30

LeMaitre Shares Drop 21.2% to $83.36

LeMaitre is down -21.2%, or -$22.42 to $83.36.

8/5 10:30

LeMaitre Shares Drop 19.6% to $85.00

LeMaitre is down -19.6%, or -$20.78 to $85.00.

8/4 16:30

2026 Revenue Forecast $274.3M-$278.3M

Sees 2026 revenue $274.3M-$278.3M, consensus $279.97M.

8/4 16:30

Company Reports Q2 Revenue of $70.4M, Below Consensus

Reports Q2 revenue $70.4M, consensus $71.47M. The company said, ""Our focus on the Artegraft international launch paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product. To underpin the Artegraft launch and pave the way for RFA, we continue to build our sales force, go direct in new countries and we're now undertaking six international warehouse expansions. $376m of cash provides strategic optionality."

8/4 16:30

Company Sees Q3 Revenue of $66.3M-$68.3M

Sees Q3 revenue $66.3M-$68.3M, consensus $69.19M.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。